Systemic effects of ocular drugs

Adverse Drug Reaction Bulletin

Volumn , Issue 215, 2002, Pages 823-826

  Cox, Anthony ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; AGENTS ACTING ON THE EYE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; CARDIOVASCULAR AGENT; CARTEOLOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID DERIVATIVE; DIPIVEFRINE; EYE DROPS; FLECAINIDE; LEVOBUNOLOL; METIPRANOLOL; MONOAMINE OXIDASE INHIBITOR; NONMIOTIC AGENT; PHENYLEPHRINE; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TRICYCLIC ANTIDEPRESSANT AGENT; TROPICAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ACUTE DISEASE; ACUTE LEUKEMIA; ACUTE PSYCHOSIS; ADRENAL SUPPRESSION; AGITATION; ALLERGY; AMNESIA; ANGINA PECTORIS; ANOREXIA; ANXIETY; APLASTIC ANEMIA; ARTIFICIAL VENTILATION; ATAXIA; ATRIOVENTRICULAR BLOCK; AUTONOMIC DYSFUNCTION; AWARENESS; BLOOD BRAIN BARRIER; BLOOD DISEASE; BLOOD DYSCRASIA; BLOOD TOXICITY; BRADYCARDIA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLUM DISEASE; CEREBROVASCULAR ACCIDENT; CONFUSION; CONVULSION; CORTICOSTEROID METABOLISM; CUSHING SYNDROME; CUSHINGOID SYNDROME; DELIRIUM; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DISORIENTATION; DISSOCIATIVE DISORDER; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG CONTROL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MARKETING; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENTIATION; DRUG RECHALLENGE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DRY SKIN; DYSARTHRIA; DYSLIPIDEMIA; ENDOCRINE DISEASE; EYE DISEASE; FAINTNESS; FALLING; FATIGUE; FEVER; FIRST PASS EFFECT; FLUSHING; GLAUCOMA; GRAND MAL SEIZURE; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART BLOCK; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HEART VENTRICLE ARRHYTHMIA; HIGH RISK POPULATION; HORMONE INHIBITION; HUMAN; HYPERACTIVITY; HYPERHIDROSIS; HYPERTENSION; HYPERVENTILATION; HYPOGLYCEMIA; HYPOTENSION; IMMUNOPATHOLOGY; INOTROPISM; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE ABNORMALITY; INTUBATION; LACRIMATION; LOW BIRTH WEIGHT; LUNG EDEMA; LUNG FUNCTION TEST; MENTAL DETERIORATION; METABOLIC DISORDER; MUSCLE WEAKNESS; MYDRIASIS; NAUSEA; NEPHROLITHIASIS; PALLOR; PATIENT EDUCATION; PRESCRIPTION; PSYCHOMOTOR DISORDER; PSYCHOMOTOR STIMULATION; RESPIRATORY ARREST; RESPIRATORY FUNCTION DISORDER; RESPIRATORY TRACT DISEASE; RESTLESSNESS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SALIVATION; SEDATION; SEIZURE; SHOCK; SIDE EFFECT; SINUS NODE DYSFUNCTION; SOMNOLENCE; SPEECH DISORDER; SWEATING; SYMPATHETIC TONE; SYNCOPE; SYSTEMIC DISEASE; TACHYCARDIA; TASTE DISORDER; THROMBOCYTOPENIA; TRANQUILIZING ACTIVITY; TRANSIENT ISCHEMIC ATTACK; TREMOR; VASOCONSTRICTION; VERTIGO; VISUAL IMPAIRMENT; VOMITING; XEROSTOMIA;

EID: 0036703016     PISSN: 00446394     EISSN: None     Source Type: Journal    
DOI: 10.1097/00012995-200208000-00001     Document Type: Review

References (64)

1. Fraunfelder FT, Fraunfelder FW. Side effects of topical ocular medication. In: Easty D, Sparrow J, editors. Oxford textbook of ophthalmology. Oxford: Oxford University Press, 1999: 80-5.
2. Vuori ML, Kaila T. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Graefes Archive for Clinical and Experimental Ophthalmology 1995; 233: 131-4.
3. Boger WPI, Puliafito CA, Steinert RF, Langston DP. Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma. Ophthalmology 1978; 85: 259-67.
4. McMahon CD, Shaffer RN, Hoskins HD, Hetherington J. Adverse effects experienced by patients taking timolol. American Journal of Ophthalmology 1979; 88: 736-8.
5. Ahmad S. Cardiopulmonary effects of timolol eyedrops. The Lancet 1979; 2: 1038.
6. Jones FL, Ekberg NL. Exacerbation of asthma by topical timolol. The New England Journal of Medicine 1979; 301: 270.
7. Van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology 1980; 87: 447-50.
8. Diggory P, Franks WA. Glaucoma therapy may take your breath away. Age and Ageing 1997; 26: 63-7.
9. Diggory P, Heyworth P, Chau G, McKenzie S, Sharma A, Luke I. Improved lung function tests on changing from topical timolol: non-selective beta-blockade impairs lung function tests in elderly patients. Eye 1993; 7: 661-3.
10. Schoene R, Verstappen A, McDonald TO. Betaxolol use not related to adverse pulmonary reactions reported in patients with reactive airway disease: A report on 12 double-masked rechallenges. Glaucoma 1992; 14: 39-45.
11. Harris LS, Greenstein SH, Bloom AF. Respiratory difficulties with betaxolol. American Journal of Ophthalmology 1986; 102: 274-5.
12. Stewart WC, Garrison PM. β-Blocker-induced complications and the patient with glaucoma. Archives of Internal Medicine 1998; 158: 221-6.
13. Vander Zanden JA, Valuck RJ, Bunch CL, Perlman JI, Anderson C, Wortman GI. Systemic adverse effects of ophthalmic β-blockers. Annals of Pharmacotherapy 2001; 35: 1633-7.
14. Leier CV, Baker N, Weber PA. Cardiovascular effects of ophthalmic timolol. Annals of Internal Medicine 1986; 104: 197-9.
15. Glynn RJ, Seddon JM, Krug JH, Sahagian CR, Chiavelli ME, Campion EW. Falls in elderly patients with glaucoma. Archives of Ophthalmology 1991; 109: 205-10.
16. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Choodnovskiy I, Avorn J. Topical glaucoma medications and cardiovascular risk in the elderly. Clinical Pharmacology and Therapeutics 1994; 55: 76-83.
17. Ball S. Congestive heart failure from betaxolol. Archives of Ophthalmology 1987; 105: 320.
18. Johns MD, Ponte CD. Acute pulmonary edema associated with ocular metipranolol use. Annals of Pharmacotherapy 1995; 29: 370-3.
19. Chamberlain TJ. Myocardial infarction after ophthalmic betaxolol. The New England Journal of Medicine 1989; 321: 1342.
20. Pringle SD, MacEwan CJ. Severe bradycardia due to interaction of timolol eye drops and verapamil. British Medical Journal 1987; 294: 155-6.
21. Minish T, Herd A. Symptomatic bradycardia secondary to interaction between topical timolol maleate, verapamil, and flecainide: a case report. Journal of Emergency Medicine 2002; 22: 247-9.
22. Orlando RG. Clinical depression associated with betaxolol. American Journal of Ophthalmology 1986; 102: 275.
23. Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Annals of Internal Medicine 1990; 112: 120-5.
24. Lynch MG, Whitson JT, Brown RH, Nguyen H, Drake MM. Topical β-blocker therapy and central nervous system side effects: a preliminary study comparing betaxolol and timolol. Archives of Ophthalmology 1988; 106: 908-11.
25. West J, Longstaff S. Topical timolol and serum lipoproteins. British Journal of Ophthalmology 1990; 74: 663-4.
26. Stewart WC, Dubiner HB, Mundorf TK, et al. Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. American Journal of Ophthalmology 1999; 127: 142-7.
27. Freedman SF, Freedman NJ, Shields MB, et al. Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol. American Journal of Ophthalmology 1993; 116: 600-11.
28. Angelo-Neilson K. Timolol topically and diabetes mellitus. Journal of the American Medical Association 1980; 244: 2263.
29. Velde TM, Kaiser FE. Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient. Archives of Internal Medicine 1983; 143: 1627.
30. Rengstorff RH, Doughty CB. Mydriatic and cycloplegic drugs: a review of ocular and systemic complications. American Journal of Optometry and Physiological Optics 1982; 59: 162-77.
31. Diamond JP. Systemic adverse effects of topical ophthalmic agents. Implications for older patients. Drugs and Ageing 1997; 11: 357-60.
32. Fraunfelder FT, Scafidi AF. Possible adverse effects from topical ocular 10% phenylephrine. American Journal of Ophthalmology 1978; 85: 447-53.
33. Solosko D, Smith RB. Hypertension following 10 per cent phenylephrine ophthalmic. Anesthesiology 1972; 36: 187-9.
34. Meyer SM, Fraunfelder FT. Phenylephrine hydrochloride. Ophthalmology 1980; 87: 1177-80.
35. Lai Y. Adverse effect of intraoperative phenylephrine 10%: case report. British Journal of Ophthalmology 1989; 73: 468-9.
36. Fraunfelder FT, Meyer SM. Possible cardiovascular effects secondary to topical ophthalmic 2.5% phenylephrine. American Journal of Ophthalmology 1985; 99: 362-3.
37. Rosales T, Isenberg S, Leake R, Everett S. Systemic effects of mydriatics in low birth weight infants. Journal of Pediatric Ophthalmology and Strabismus 1981; 18: 42-4.
38. Kohn AN, Moss AP, Hargett NA, Ritch R, Smith H, Podos SM. Clinical comparison of dipivalyl epinephrine and epinephrine in the treatment of glaucoma. American Journal of Ophthalmology 1979; 87: 196-201.
39. Kerr CR, Hass I, Drance SM, Walters MB, Schulzer M. Cardiovascular effects of epinephrine and dipivalyl epinephrine applied topically to the eye in patients with glaucoma. British Journal of Ophthalmology 1982; 66: 109-14.
40. Nelson ME, Andrzejowski AZ. Systemic hypertension in patients receiving dipivalyl adrenaline for glaucoma. British Medical Journal 1988; 297: 741-2.
41. Robin AL, Burnstein Y. Selectivity of site of action and systemic effects of topical alpha agonists. Current Opinion in Ophthalmology 1998; 9: 30-3.
42. Korsch E, Grote A, Seybold M, Soditt V. Systemic effects of topical treatment with brimonidine in an infant with secondary glaucoma. European Journal of Pediatrics 1999; 158: 685.
43. Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clinical Therapeutics 2000; 22: 167-208.
44. Littman L, Kempler P, Rohla M, Fenyvesi T. Severe symptomatic atrioventricular block induced by pilocarpine eye-drops. Archives of Internal Medicine 1987; 147: 586-7.
45. Martin XD, Danese M. Dorzolamide-induced immune thrombocytopenia: a case report and literature review. Journal of Glaucoma 2001; 10: 133-5.
46. Kennerdell JS, Wucher FP. Cyclopentolate associated with two cases of grand mal seizure. Archives of Ophthalmology 1972; 87: 634-5.
47. Khurana AK, Ahluwlia MS, Rajan C, Vohra AK. Acute psychosis associated with topical cyclopentolate hydrochloride. American Journal of Ophthalmology 1988; 105: 91.
48. Delberghe X, Zegers De Beyl D. Repeated delirium from homatropine eye-drops. A case report. Clinical Neurology and Neurosurgery 1987; 89: 53-4.
49. Falbe WJ, Boyd DL. Homatropine-associated confusion in an elderly patient. Journal of the American Geriatric Society 1988; 36: 649.
50. Carpenter WT. Precipitous mental deterioration following cycloplegia with 0.2% cyclopentolate HCl. Archives of Ophthalmology 1967; 78: 445-7.
51. Vuori ML, Kaila T, Iisalo E, Saari KM. Systemic absorption and anticholinergic activity of topically applied tropicamide. Journal of Ocular Pharmacology 1994; 10: 431-7.
52. Vicedo F, Garcia B, Beliver G, Bustamante P. Conjunctival tropicamide and transitory ischaemic accident. Farmacia Clinica 1998; 15: 115-18.
53. Brunner GA, Fleck S, Pieber TR, et al. Near fatal anticholinergic intoxication after routine fundoscopy. Intensive Care Medicine 1998; 24: 730-1.
54. Mitra M, Chang B, James T. Exacerbation of angina associated with latanoprost. British Medical Journal 2001; 323: 783.
55. Peak AS, Sutton BM. Systemic adverse effects associated with topically applied latanoprost. Annals of Pharmacotherapy 1998; 32: 504-5.
56. Fraunfelder FT, Bagby GC, Kelly JP. Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol. American Journal of Ophthalmology 1982; 93: 356-60.
57. Fraunfelder FT, Morgan RL, Yunis AA. Blood dycrasias and topical ophthalmic chloramphenicol. American Journal of Ophthalmology 1993; 115: 813.
58. Doona M, Walsh JB. Use of chloramphenicol as topical eye medication: time to cry halt? British Medical Journal 1995; 310: 1217-18.
59. Doona M, Walsh JB. Topical chloramphenicol is an outmoded treatment. British Medical Journal 1998; 316: 1903.
60. McGhee CNJ, Anastas CN. Widespread ocular use of topical chloramphenicol: is there justifiable concern regarding idiosyncratic aplastic anaemia? British Journal of Ophthalmology 1996; 80: 182-4.
61. Lancaster T, Swart AM, Jick H. Risk of serious haematological toxicity with use of chloramphenicol eye-drops in a British general practice database. British Medical Journal 1998; 316: 667.
62. Wilholm B, Kelly JP, Kaufman D, et al. Relation of aplastic anaemia to use of chloramphenicol eye drops in two international case-control studies. British Medical Journal 1998; 316: 666.
63. Smith AG, Dovey GJ, Cartwright RA. Topical chloramphenicol and the risk of acute leukaemia in adults. Pharmacoepidemiology and Drug Safety 2000; 9: 215-19.
64. O'Day DM, McKenna TJ, Elliott JH. Ocular corticosteroid therapy: systemic hormonal effects. Transactions of the American Academy of Ophthalmology and Otolaryngology 1975; 79: 71-7.